Google
Trusted Resources: News & Events
Latest announcements and gatherings
MaxCyte, Inc. to Present Positive Preclinical Data for Sickle Cell Disease
MaxCyte, a US-based global company dedicated to driving the acceleration of discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, announced today it will present positive preclinical study results at the American Society of Gene and Cell Therapy Annual Meeting (ASGCT). The new in vitro data demonstrate the potential of MaxCyte’s cGMP-compliant proprietary delivery platform to enable CRISPR gene editing in the treatment of sickle cell disease (SCD). The ASGCT meeting will take place in Washington, DC from May 10-13, 2017.
+myBinderRelated Content
-
Hospitals See No Link Between US Opioid Crisis and Patients’ Use of Treatment, Study ReportsThe U.S. opioid epidemic is not linked t...
-
Benign Hematologic Disorders in Children, an Issue of Pediatric Clinics of North America, Volume 65-3This issue will provide a current update...
-
Beliefs about hydroxyurea in youth with sickle cell diseaseBackground: Hydroxyurea reduces complic...
-
bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene ...Patient treated with LentiGlobinTM drug ...
-
Investigational Oral Inhibitor IMR-687 Shows Promising Results in Ongoing Phase 2 Clinical TrialImara’s investigational oral inhibitor...
-
SCDAA News Advisory: Partial Hold on Gene Therapy TrialOn December 20, the FDA placed a partial...
-
Gamida Cell Announces $3.5 Million Grant from the Israeli GovernmentGamida Cell, a leader in cellular and im...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.